Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

HIV Medicine

Volumn 16, Issue S1, 2015, Pages 30-36

  Sharma, S ^a   Babiker, Ag ^b   Emery, S ^c   Gordin, Fm ^d   Lundgren, Jd ^e   Neaton, Jn ^a   Bakowska, E ^f   Schechter, M ^g   Wiselka, Mj ^h   Wolff, Mj ⁱ  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Wojewodzki Szpital Zakazny   (Poland)

^g FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^h LEICESTER ROYAL INFIRMARY   (United Kingdom)

ⁱ UNIVERSITY OF CHILE   (Chile)

Author keywords

Clinical trial; HIV; START trial; When to start antiretroviral therapy

Indexed keywords

ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RNA;

ACUTE HEART INFARCTION; ADULT; ALCOHOLISM; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DRUG USE; END STAGE RENAL DISEASE; FATTY LIVER; FEMALE; HEART MUSCLE REVASCULARIZATION; HETEROSEXUALITY; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEN WHO HAVE SEX WITH MEN; MENTAL DISEASE; MYOCARDITIS; PANCREATITIS; PERICARDITIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SELF INJECTION; SKIN CANCER; SUBSTANCE ABUSE; CLINICAL TRIAL; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DEMOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923344486     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12231     Document Type: Article

References (22)

1. Cooper DA, Gatell JM, Kroon S etal. Zidovudine in persons with asymptomatic HIV infection and CD4 cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329: 297-303.
2. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double blind controlled trial or immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-881.
3. Volberding PA, Lagakos SW, Grimes JA etal. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995; 333: 401-407.
4. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report 2013. UNAIDS report on the global AIDS epidemic 2013.
5. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report 2010. UNAIDS report on the global AIDS epidemic 2010.
6. Pacheco AG, Tuboi SH, Faulhaber JC etal. Increase in non-AIDS related conditions as Causes of Death among HIV-Infected Individuals in the HAART era in Brazil. PLoS ONE 2008; 3: e1531.
7. Palella FJ Jr, Baker RK, Moorman AC etal. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
8. Smith CJ, Ryom L, Weber R etal. Trends in underlying causes of death in people with HV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384: 241-248.
9. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22: 2409-2418.
10. Babiker AG, Emery S, Fätkenheuer G etal. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013; 10 (Suppl 1): S5-S36.
11. Law MG, Achhra A, Deeks SG etal. Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 37-45.
12. United States Centers for Disease Control and Prevention (CDC). [Internet]. HIV in the United States: At a Glance; 2013. Available at http://www.cdc.gov/hiv/statistics/basics/ataglance.html (accessed 24 March 2014).
13. European Center for Disease Prevention and Control (ECDC)/World Health Organization (WHO) Regional Office for Europe. Surveillance Report. HIV/AIDS surveillance in Europe 2012.
14. The Kirby Institute. Annual Surveillance Report 2012. HIV, viral hepatitis and sexually transmissible infections in Australia. University of New South Wales, Sydney, Australia.
15. Joint United Nations Programme on HIV/AIDS (UNAIDS). HIV in Asia and the Pacific. UNAIDS report 2013.
16. Severe P, Juste MAJ, Ambroise A etal. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363: 257-265.
17. Cohen MS, Chen YQ, McCarley M etal. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
18. Grinsztejn B, Hosseinipour M, Ribaudo H etal. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomized controlled trial. Lancet Infect Dis 2014; 14: 281-290.
19. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major Clinical Outcomes in Antiretroviral Therapy (ART) - Naïve Participants and in Those Not Receiving ART at Baseline in the SMART Study. J Infect Dis 2008; 197: 1133-1144.
20. Temprano ANRS 12136 [Internet]. France: Temprano clinical trial; [date unknown]. Available at http://mereva.isped.u-bordeaux2.fr/temprano/ (accessed 19 July 2014).
21. Jean K, Gabillard D, Moh R etal. Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in Côte d'Ivoire. J Int AIDS Soc 2014; 17: 18977.
22. INSIGHT START Study Group. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med 2015; 16 (Suppl 1): 1-9.